menu
    • menu

    Company profile for Bioeq IP AG

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    Moehs Group, a reference company in the production of pharmaceutical active ingredients.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Bioeq IP AG is a Swiss biopharmaceutical joint venture between the leading Polish pharmaceutical group Polpharma and the Strüngmann family’s investment company. Bioeq licenses, develops and commercializes biological successor products of successful biopharmaceuticals, called biosimilars. FYB201 is currently the most advanced biosimilar program of Bioeq. The clinical studies and registration are conducted by a subsidiary, Bi...
    Bioeq IP AG is a Swiss biopharmaceutical joint venture between the leading Polish pharmaceutical group Polpharma and the Strüngmann family’s investment company. Bioeq licenses, develops and commercializes biological successor products of successful biopharmaceuticals, called biosimilars. FYB201 is currently the most advanced biosimilar program of Bioeq. The clinical studies and registration are conducted by a subsidiary, Bioeq GmbH based in Holzkirchen, Germany, on behalf of Bioeq IP AG.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Bioeq IP AGSwitzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    Waldmannstrasse 8 8001 Zurich
    Telephone
    Telephone
    +41 44 533 41 00
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://bioeq.ch/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/bioeq-ip-ag
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Zydus & Bioeq Partner for US NUFYMCO Launch
    Zydus & Bioeq Partner for US NUFYMCO Launch

    23 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/zydus-partners-with-bioeq-for-us-commercialisation-rights-for-nufymco-an-interchangeable-biosimilar-to-lucentis-302648783.html

    PR NEWSWIRE
    23 Dec 2025
    Share Share
    Bio Usawa, Bioeq Partner to Expand Vision Drug Access in Africa
    Bio Usawa, Bioeq Partner to Expand Vision Drug Access in Africa

    01 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/01/3108221/0/en/Bio-Usawa-Biotechnology-and-Bioeq-AG-Partner-to-Create-Widespread-Access-to-Vision-Saving-Medicine-Across-Sub-Saharan-Africa.html

    GLOBENEWSWIRE
    01 Jul 2025
    Share Share
    FDA Approves First Biosimilar to Lucentis
    FDA Approves First Biosimilar to Lucentis

    03 Aug 2022

    // CONTRACTPHARMA

    https://www.contractpharma.com/contents/view_breaking-news/2022-08-03/fda-approves-first-biosimilar-to-lucentis/?widget=listSection

    CONTRACTPHARMA
    03 Aug 2022
    Share Share
    Teva Receives Approval for First Ophthalmology Biosimilar in Europe
    Teva Receives Approval for First Ophthalmology Biosimilar in Europe

    20 May 2022

    // J. Nutovits LEXBLOG

    https://www.lexblog.com/2022/05/19/teva-receives-approval-for-first-ophthalmology-biosimilar-in-europe/

    J. Nutovits LEXBLOG
    20 May 2022
    Share Share
    FDA Accepts Review of Polpharma & Bioeq's BLA of Ranibizumab
    FDA Accepts Review of Polpharma & Bioeq's BLA of Ranibizumab

    04 Oct 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211004005408/en/Polpharma-Biologics-Group-Announces-that-the-Biologics-License-Application-BLA-Submitted-by-its-Joint-Venture-Bioeq-for-its-Biosimilar-Ranibizumab-has-Been-Accepted-for-Review-by-the-U.S.-Food-and-Drug-Administration-FDA

    BUSINESSWIRE
    04 Oct 2021
    Share Share
    Polpharma & Bioeq Joint Venture Submission of Biosimilar Ranibizumab BLA to FDA
    Polpharma & Bioeq Joint Venture Submission of Biosimilar Ranibizumab BLA to FDA

    06 Aug 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210806005315/it

    BUSINESSWIRE
    06 Aug 2021
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search